AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CONMED Exits Gastroenterology Portfolio, Reaffirms 2025 Outlook with 80 Basis Points Margin Boost
ByAinvest
Friday, Dec 5, 2025 9:03 am ET1min read
CONMED plans to exit its gastroenterology portfolio to focus on core markets. The portfolio is expected to generate $90-95mln in revenue in 2025 with 45% gross margins. The exit will dilute EPS by $0.45-$0.55 in 2026 but lift consolidated gross margins by 80 basis points. Proceeds will be used for strategic investments, debt reduction, and share buybacks. The company reaffirmed its 2025 revenue guidance of $1.365bln-$1.372bln and adjusted EPS of $4.48-$4.53.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet